These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34166595)

  • 1. Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators.
    Huppertsberg A; Kaps L; Zhong Z; Schmitt S; Stickdorn J; Deswarte K; Combes F; Czysch C; De Vrieze J; Kasmi S; Choteschovsky N; Klefenz A; Medina-Montano C; Winterwerber P; Chen C; Bros M; Lienenklaus S; Sanders NN; Koynov K; Schuppan D; Lambrecht BN; David SA; De Geest BG; Nuhn L
    J Am Chem Soc; 2021 Jul; 143(26):9872-9883. PubMed ID: 34166595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.
    Nuhn L; Vanparijs N; De Beuckelaer A; Lybaert L; Verstraete G; Deswarte K; Lienenklaus S; Shukla NM; Salyer AC; Lambrecht BN; Grooten J; David SA; De Koker S; De Geest BG
    Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8098-103. PubMed ID: 27382168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-Decorated Degradable Polycarbonate Nanogels for Eliciting Antigen-Specific Immune Responses.
    Stickdorn J; Czysch C; Medina-Montano C; Stein L; Xu L; Scherger M; Schild H; Grabbe S; Nuhn L
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.
    Nuhn L; Van Hoecke L; Deswarte K; Schepens B; Li Y; Lambrecht BN; De Koker S; David SA; Saelens X; De Geest BG
    Biomaterials; 2018 Sep; 178():643-651. PubMed ID: 29573820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control over Imidazoquinoline Immune Stimulation by pH-Degradable Poly(norbornene) Nanogels.
    Kockelmann J; Stickdorn J; Kasmi S; De Vrieze J; Pieszka M; Ng DYW; David SA; De Geest BG; Nuhn L
    Biomacromolecules; 2020 Jun; 21(6):2246-2257. PubMed ID: 32255626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.
    Stickdorn J; Stein L; Arnold-Schild D; Hahlbrock J; Medina-Montano C; Bartneck J; Ziß T; Montermann E; Kappel C; Hobernik D; Haist M; Yurugi H; Raabe M; Best A; Rajalingam K; Radsak MP; David SA; Koynov K; Bros M; Grabbe S; Schild H; Nuhn L
    ACS Nano; 2022 Mar; 16(3):4426-4443. PubMed ID: 35103463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels.
    Scherger M; Bolli E; Antunes ARP; Arnouk S; Stickdorn J; Van Driessche A; Schild H; Grabbe S; De Geest BG; Van Ginderachter JA; Nuhn L
    Cells; 2020 Oct; 9(10):. PubMed ID: 33019594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methionine-Based pH and Oxidation Dual-Responsive Block Copolymer: Synthesis and Fabrication of Protein Nanogels.
    Dong S; Jiang Y; Qin G; Liu L; Zhao H
    Biomacromolecules; 2020 Oct; 21(10):4063-4075. PubMed ID: 32914964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
    Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
    Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxymethyl chitosan-based nanogels via acid-labile ortho ester linkages mediated enhanced drug delivery.
    Li S; Hu L; Li D; Wang X; Zhang P; Wang J; Yan G; Tang R
    Int J Biol Macromol; 2019 May; 129():477-487. PubMed ID: 30771386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid-degradable lactobionic acid-modified soy protein nanogels crosslinked by ortho ester linkage for efficient antitumor in vivo.
    Cheng X; Qin J; Wang X; Zha Q; Yao W; Fu S; Tang R
    Eur J Pharm Biopharm; 2018 Jul; 128():247-258. PubMed ID: 29730261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles-TLR7/8 Agonist Conjugates.
    Van Herck S; Deswarte K; Nuhn L; Zhong Z; Portela Catani JP; Li Y; Sanders NN; Lienenklaus S; De Koker S; Lambrecht BN; David SA; De Geest BG
    J Am Chem Soc; 2018 Oct; 140(43):14300-14307. PubMed ID: 30277761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination.
    Xia H; Qin M; Wang Z; Wang Y; Chen B; Wan F; Tang M; Pan X; Yang Y; Liu J; Zhao R; Zhang Q; Wang Y
    Nano Lett; 2022 Apr; 22(7):2978-2987. PubMed ID: 35302770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-sensitive and tumor-targeting nanogels based on ortho ester-modified PEG for improving the in vivo anti-tumor efficiency of doxorubicin.
    Wang X; Zheng Y; Xue Y; Wu Y; Liu Y; Cheng X; Tang R
    Colloids Surf B Biointerfaces; 2021 Nov; 207():112024. PubMed ID: 34384973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
    Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor-7/8 agonist kill Leishmania amazonensis by acting as pro-oxidant and pro-inflammatory agent.
    Kaushik D; Granato JT; Macedo GC; Dib PRB; Piplani S; Fung J; da Silva AD; Coimbra ES; Petrovsky N; Salunke DB
    J Pharm Pharmacol; 2021 Aug; 73(9):1180-1190. PubMed ID: 33940589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
    Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
    Kim H; Griffith TS; Panyam J
    J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.
    Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA
    Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.